Search results
15 sty 2014 · KRAS mutations activate RAS proteins that continuously stimulate the signalling pathways in the absence of upstream stimulation of EGFR (constitutive activation). Consequently, tumours bearing a KRAS mutation are less likely to respond to anti-EGFR drugs .
We evaluated EGFR expression at protein and mRNA levels in canine intestinal adenocarcinomas using immunohistochemistry (IHC) and RNA in situ hybridization (RNA-ISH). We also investigated the mutation status of EGFR, KRAS, and BRAF to aid the development of anti-EGFR agents for canine intestinal adenocarcinoma.
30 kwi 2021 · The EGFR, KRAS, and BRAF genes showed wild-type sequences at the mutation hot spots in all 13 specimens. Thus, EGFR might serve as a promising diagnostic marker in canine intestinal adenocarcinoma, and further studies would be needed to develop EGFR-targeted anticancer therapies.
15 sty 2014 · Epidermal growth factor receptor (EGFR or HER-1) and its analog c-erbB-2 (HER-2) are protein tyrosine kinases correlated with prognosis and response to therapy in a variety of human cancers. KRAS mediates the transduction of signals between EGFR and the nucleus, and its mutation has been identified …
The presence of EGFR and KRAS mutations was detected using the Human EGFR Gene Mutation Detection kit and the Human KRAS Gene Mutation Detection kit (Fluorescent polymerase chain reaction; both from Beijing ACCB Biotech Ltd., Beijing, China), which was approved by the State Food and Drug Administration for clinical application in China ...
19 sty 2023 · BRAF mutant tumors had a better prognosis when treated with lapatinib (EGFR and ERBB2 inhibitor) (OS HR 0.10, P = 0.02) and ARID1A with trametinib (MEK1/2 inhibitor) (OS HR 0.08, P = 0.02...
14 lis 2019 · Epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (K-RAS) are two of the main significant biomarkers for the management of NSCLC. Mutations in these genes were associated with development and response to therapies.
